BioSpace News Archive

Vitality Biopharma announced the publication of an international PCT patent application that covers a new class of cannabinoid pharmaceuticals.

Trillium Therapeutics announced today that new preclinical data and a patient case study for its CD47-blocking agent, TTI-621 (SIRPa-IgG1 Fc), were presented at the EORTC CLTF meeting “Cutaneous Lymphomas - Insights and Therapeutic Progress”, October 13-15, in London, England.

Aimmune Therapeutics, Inc., today announced a clinical collaboration with Regeneron and its strategic alliance collaborator Sanofi to study AR101 treatment with adjunctive dupilumab in peanut-allergic patients in a Phase 2 clinical trial.

BrainStorm Cell Therapeutics today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn for the treatment of amyotrophic lateral sclerosis (ALS) at the Massachusetts General Hospital and UC Irvine Medical Center in California.

QIAGEN N.V. plans as previously announced to release its report on results for the third quarter and first nine months of 2017 on Monday, November 6 at approximately 22:00 Central European Time (CET) / 16:00 Eastern Time (EDT).

Sigilon Therapeutics today announced the formation of a scientific advisory board.

Shifamed LLC announced that Apama Medical was acquired by Boston Scientific Corporation for $175M in cash up-front and a maximum of $125M in contingent payments over the period of 2018-2020, based on achievements of clinical and regulatory milestones.

Aethlon Medical announced today that it has established a collaboration with iBio to support potential large-scale production of the Aethlon Hemopurifier.

AVEO Oncology today announced that results from the Phase 1 portion of the Phase 1/2 TiNivo study will be presented in an oral presentation at the 16th International Kidney Cancer Symposium, to be held November 3-4, 2017 in Miami.

ArQule, Inc. today announced the closing of a private placement with certain institutional investors, with leading participation by BVF Partners L.P., pursuant to which the Company raised gross proceeds of approximately $15.7 million through the sale of 13,938,651 shares of common stock and 3,123,674 warrants.